---
title: Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
nct_id: NCT01104675
overall_status: COMPLETED
phase: PHASE2
sponsor: CASI Pharmaceuticals, Inc.
study_type: INTERVENTIONAL
primary_condition: Ovarian Cancer
countries: United States, Canada
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01104675.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01104675"
ct_last_update_post_date: 2014-08-06
last_seen_at: "2026-05-12T06:28:17.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer

**Official Title:** A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer

**NCT ID:** [NCT01104675](https://clinicaltrials.gov/study/NCT01104675)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 64
- **Lead Sponsor:** CASI Pharmaceuticals, Inc.
- **Conditions:** Ovarian Cancer, Fallopian Cancer, Peritoneal Cancer
- **Start Date:** 2010-04
- **Completion Date:** 2012-12
- **CT.gov Last Update:** 2014-08-06

## Brief Summary

The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Have histologically documented diagnosis of ovarian, fallopian or peritoneal cancer that is platinum resistant.
* Have a pre-study echocardiogram or multigated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institution lower limit of normal
* Greater than or equal to 18 years of age
* Have clinically acceptable laboratory screening results
* Have an ECOG performance status of 0 or 1
* Able to tolerate oral medications

Exclusion Criteria:

* Have uncontrolled hypertension (systolic blood pressure greater than 150mmHg or diastolic blood pressure greater than 100mmHg); require two or more antihypertensive medications to control hypertension (including ACE inhibitors, beta blockers, calcium channel blockers, or diuretics)
* Have chronic atrial fibrillation or QTc interval corrected for heart rate of greater than 470 msec
* Have active, acute, or chronic clinically significant infections or bleeding
* Have persistent 2+ protein by urinalysis or a history of nephrotic syndrome
```

## Arms

- **ENMD-2076 treatment** (EXPERIMENTAL)

## Interventions

- **ENMD-2076** (DRUG) — 275 mg (or 250 mg for BSA \< 1.65) per day in oral capsules in 28 day continuous cycles

## Primary Outcomes

- **Progression free survival rate** _(time frame: 6 months)_

## Locations (6)

- University of Colorado Cancer Center, Aurora, Colorado, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
- Dana Farber/Partners Cancer Care, Boston, Massachusetts, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Princess Margaret Hospital, Toronto, Ontario, Canada

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of colorado cancer center|aurora|colorado|united states` — added _(2026-05-12)_
- `locations.university of chicago medical center|chicago|illinois|united states` — added _(2026-05-12)_
- `locations.indiana university simon cancer center|indianapolis|indiana|united states` — added _(2026-05-12)_
- `locations.dana farber/partners cancer care|boston|massachusetts|united states` — added _(2026-05-12)_
- `locations.memorial sloan-kettering cancer center|new york|new york|united states` — added _(2026-05-12)_
- `locations.princess margaret hospital|toronto|ontario|canada` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01104675.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01104675*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*